Aducanumab In The News
- 4/11/2022: CMS Released Final Decision on Aduhelm
- 2/24/2022: Should People With Down Syndrome Demand Coverage Of Aduhelm For Them?
- 1/11/2022: CMS announces decision on anti-amyloid monoclonal antibodies
- 7/15/2021: Aducanumab update
- 6/24/2021: A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
- 6/17/2021: Furor rages over FDA approval of controversial Alzheimer’s drug
- 6/10/2021: The FDA has approved Aduhelm. What now?
- 6/7/2021: The Problem With Post-Approval Required Studies
- 6/7/2021: The FDA Has Approved Aducanumab (Aduhelm™). Now What?
- 5/18/2021: MIND Matters | Quarterly Newsletter | Spring 2021 (Message from the Director, What are monoclonal antibodies?)
- 11/20/2020: Aducanumab Still Needs to Prove Itself, Researchers Say
- 11/16/2020: MIND Matters | Quarterly Newsletter | Fall 2020 (Message from the Director)
- 11/6/2020: FDA Advisory Panel Recommends Against Approval of Aducanumab for the Treatment of Alzheimer’s Disease
- 11/6/2020: FDA Meets Today To Review Aducanumab For The Treatment Of Alzheimer’s
- 7/8/2020: Biogen And Eisai Submit Aducanumab For FDA Approval
- 11/8/2019: Another Hopeful Outcome For Alzheimer’s Treatment
- 11/6/2019: Updates On Biogen’s Aducanumab From CTAD
- Fall 2019: MIND Matters | Quarterly Newsletter | Fall 2019 (Message from the Director)
- 10/23/2019: Biogen’s About Face
- Spring 2019: MIND Matters | Quarterly Newsletter | Spring 2019 (Message from the Director)
- 3/21/19: Phase 3 Trials Of Aducanumab Halted
- Winter 2018: MIND Matters | Quarterly Newsletter | Winter 2018 (Despite “Flops,” Clinical Trials Bring Hope)
- Winter 2017: MIND Matters | Quarterly Newsletter | Winter 2017 (Anti-Amyloid Therapies: Where Are We Now?)
- Fall 2016: MIND Matters | Quarterly Newsletter | Fall 2016 (Aducanumab: A Call for Cautious Enthusiasm)
- 9/1/2016: Investigational antibody treatment yields exciting though preliminary results
